The rise in GLP-1 drugs is undeniable. Morgan Stanley projects that by 2035, 24 million Americans, or 7% of the population, ...
Microdosing glp-1 is gaining traction, but is it safe? Experts warn about compounded semaglutide, reduced efficacy, and ...
Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...
As GLP-1 medications such as Ozempic, Mounjaro and Wegovy rise in popularity, so do concerns over their side effects.
GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.
Almost no other industry goes as far as the phrase "defensive" as the healthcare sector, which encompasses a wide range of ...
In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...
Generic drugmaker Granules India is foraying into the peptide segment and contract development and manufacturing organisation (CDMO) business with a ₹192.5 crore (CHF 20 million) acquisition of Swiss ...
The clinical Phase I study conducted in the NEX-22 project with good results and focus on the evaluation with Novo Nordisk has provided a good starting point for 2025. Significant events during the fo ...
For its entry into fast growing peptide segment and strengthen its CDMO biz ...
Pharma major, Granules India on Saturday said that its board has approved to acquire 100% stake in Senn Chemicals AG, a Swizterland based company, for a total consideration of Rs 192.5 crore. Krishna ...
Granules India said that its board has approved to acquire 100% stake in Senn Chemicals AG, a Swizterland based company, for a total consideration of Rs 192.5 crore (CHF 20 million).